Over the last 2 years there has been a rise in the interest in investigating the use of psychedelic compounds (Psilocybin, LSD, DMT & MDMA) for medical use especially with regard to aiding in various types of therapy for a range of issues such as PTSD, depression and dealing with addiction issues regarding alcohol, opioids and other substances.
Concurrent with medical interest legislative and legal issues have begun to come into play as cities and states around the country along with advocacy bodies are looking at ways to remove these compounds from existing criminal statutes.
Many lawyers with a background in the maturing cannabis industry are also now applying their skills and knowledge to the world of psychedelics and advising companies, authorities and governments on the paths to de-criminalization, regulation and markets.
A significant development in this new field of law is the funding of the The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. The centre is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics.
Launched in summer 2021 with a grant from the Saisei Foundation, the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy.
They say…..”Due to their therapeutic and commercial potential, the U.S. market for psychedelics is projected to reach $6.85 billion by 2027, attracting a significant number of for-profit companies and investors. However, despite the proliferation of clinical research centers, increasing private investment in psychedelic drug development, and widespread state and local decriminalization, there is a relative lack of research on the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics.”
For further background please read
Judith H. Kuch, who avers she is an “ordained minister of the Neo-American Church”, stands indicted in a seven-count indictment for unlawfully obtaining and transferring marihuana and for the unlawful sale, delivery and possession of LSD. She moves to dismiss on several grounds… Click to see more
Henry E. Routon appeals the circuit court’s judgment convicting him of one count of conspiracy to manufacture psilocybin/psilocin contrary to Psilocybin and psilocin are hallucinogenic substances that are produced by psilocybe mushrooms. Routon contends that the evidence presented in the trial to the court was insufficient to prove that he conspired to manufacture… Click to see more
Two cases consolidated for decision in banc present three questions concerning the application and constitutionality of the statute and sentencing guidelines that govern sales of lysergic acid diethylamide (LSD). Stanley J. Marshall was convicted after a bench trial and sentenced to 20 years’ imprisonment for conspiring to distribute, and distributing, more than ten grams of LSD, enough for 11,751 doses… Click to see more
Following a bench trial, Defendant-Appellant Daahir Caseer was convicted on May 15, 2002 of one count of conspiring to import cathinone and one count of aiding and abetting the importation of cathinone. The district court sentenced Caseer to two years’ probation… Click to see more
Celeb Stoner is reporting the following.. The man who’s trying to legalize psychedelic drugs in New York State has been arrested for having them. On
The leader of the New Jersey Senate filed a bill on Thursday that would legalize the possession, home cultivation and gifting of psilocybin mushrooms for
Psychedelic Spotlight reports Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin. Ever since Compass Pathways
Two ballot initiatives dealing with the decriminalization and regulation of psychedelics in Colorado might appear on this year’s November ballot. Initiative 61 and Initiative 58
A new academic center in the College of Social Work at The Ohio State University aims to fill two gaps in the burgeoning field of
The Multi-organization psychedelic partnership is set to launch on June 23 2022 A new alliance aiming to help hone the therapeutic potential of psychedelics is set to
IP Due Diligence in a Psychedelics Transaction: An Evolving Rulebook By Jayashree Mitra, Ph.D., Partner, Fox Rothschild LLP The market for psychedelic substances is projected to grow
The survivors of an Airdrie man whose final days were made easier by sanctioned magic mushroom therapy have filed a lawsuit claiming his cancer-related death
In “Psychedelics Legislation and Regulation,” panelists discussed emerging state and federal psychedelics legislation, drug policy reform, and the oversight of psychedelics research and development by
Umm? On Tuesday, Mydecine’s CEO, David Joshua Bartch (who generally goes by ‘Josh Bartch’), filed more than 10 insider transaction notices, the earliest of which
Disclaimer: The views and opinions expressed in AnyLaw Case Summaries and Law Thoughts are those of the authors and do not necessarily reflect the official policy or position of this website.
Articles do not constitute legal advice.
© Lexsphere LTD. Reproduction of the material contained in this publication may be made only with the written permission of Lexsphere LTD.
